Caitlin Raymond on Platelet Refractoriness: New Series Alert!
Caitlin Raymond, a board-certified Clinical Pathologist and current Transfusion Medicine Fellow at the National Institutes of Health, shared on LinkedIn:
“New Blog Post: Platelet Refractoriness — An Overview
One of the most frustrating challenges in transfusion medicine is when platelet transfusions don’t “stick.”
Platelet refractoriness is common, multifactorial, and has huge implications for bleeding risk, patient outcomes, and stewardship of scarce blood products.
In this post, I walk through:
- How we define and measure refractoriness (CCI)
- Why non-immune causes (like sepsis, bleeding, or splenomegaly) are the most common and should be ruled out first
- How we evaluate immune causes with HLA typing, antibody screens, PRA, and crossmatches
- Practical management strategies, from HLA-compatible platelets to PRA-guided selection
- The real-world challenges of balancing ideal care with limited resources
Key takeaway: Refractoriness isn’t rare—and a structured approach can make transfusion both safer for patients and more sustainable for the blood supply.”
Read the full post here.
More from Caitlin Raymond featured in HT!
More series on coagulation featured in Hemostasis Today.
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies
-
Jan 12, 2026, 01:55Frank Weinz on State-of-the-Art Thromboembolism Prophylaxis